Showing 5341-5350 of 8729 results for "".
- Does Vitiligo-associated Autoimmunity Reduce Morbidity and Mortality?https://practicaldermatology.com/news/does-vitiligo-associated-autoimmunity-reduced-morbidity-and-mortality/2462014/Vitiligo-associated autoimmunity may play a role in reducing morbidity and mortality, according to a study in the Journal of Investigative Dermatology. When researchers investigated the mortality of patients with vitiligo in a population-base
- PFAS Exposure Linked to Melanoma in Womenhttps://practicaldermatology.com/news/pfas-exposure-linked-to-melanoma-in-women/2462011/Exposure to PFAS (per- and poly-fluoroalkyl substances) and phenols may be linked to diagnoses of melanoma and other cancers, new research suggests. Women who reported higher levels of exposure to PFDE, a long-chained PFAS compound, had double the odds of a previous melanoma diagnosis;
- Positive Topline Results Seen for Roflumilast Cream 0.05% in Young Kidshttps://practicaldermatology.com/news/positive-topline-results-seen-for-roflumilast-cream-005-in-young-kids/2462010/Arcutis Biotherapeutics, Inc.’s roflumilast cream 0.05% met all primary endpoint and all secondary endpoints in children aged 2 to 5 years with mild to moderate atopic dermatitis (AD), according to results from the INTEGUMENT-PED pivotal Phase 3 trial. In
- Study: AD Ups Risk for IBDhttps://practicaldermatology.com/news/study-ad-ups-risk-for-ibd/2462009/Adults with atopic dermatitis (AD) have a 34% increased risk of developing new-onset inflammatory bowel disease (IBD) compared with individuals who do not have the skin condition, and children have a 44% increased risk, according to a new study from the P
- MTX vs. CsA in AD: Which Is Best for Kids?https://practicaldermatology.com/news/mtx-vs-csa-in-ad-which-is-best-for-kids/2462008/Methotrexate bested cyclosporine in children with severe atopic dermatitis, a new study shows. While new systemic therapies for AD are being introduced, researchers want to est
- ‘SUNucate’ Laws Do Increase Interest in Sun Protection, Youth Sunscreen Usehttps://practicaldermatology.com/news/sunucate-laws-do-increase-interest-in-sun-protection-youth-sunscreen-use/2461998/States that enacted SUNUCATE laws permitting children to carry and apply sunscreen at school experienced an increased interest in sun protection and a higher rate of sunscreen use among adolescents, according to new research by a University of Massachusetts Amherst resource economist.
- Hillstream Enters Into an Exclusive Option Agreement to Acquire a Clinical Stage Asset for Chronic Pruritishttps://practicaldermatology.com/news/hillstream-enters-into-an-exclusive-option-agreement-to-acquire-a-clinical-stage-asset-for-chronic-pruritis/2461994/Hillstream BioPharma, Inc. is set to acquire AV104 for chronic pruritis. AV104 has a dual mechanism of action by affecting multiple receptors, known to suppress chronic, debilitating pruritis. The Company intends to first seek approval in an orphan disease for the treatment of mode
- ABMS Announces Class of 2023-2024 Visiting Scholarshttps://practicaldermatology.com/news/abms-announces-class-of-2023-2024-visiting-scholars/2461993/Gillian Heinecke, MD, an assistant clinical professor at SSM Health/Saint Louis University in St. Louis, Mo. is the American Board of Dermatology’s 2023-2024 Visiting Scholar. The American Board of Medical Specialties (ABMS) selected thirteen outstanding indivi
- The Complexion of Climate in Medical Educationhttps://practicaldermatology.com/news/the-complexion-of-climate-in-medical-education/2461992/The morning news warned us of a heatwave, but that didn’t stop 8-year-old me from putting on my usual red hoodie. The avoidance of prying eyes or hearing “is it contagious?” another time made the sweating worth it. Atopic dermatitis (AD) had claimed my skin as its home, marking
- DermTech Appoints Mark Aguillard as Chief Commercial Officerhttps://practicaldermatology.com/news/dermtech-appoints-mark-aguillard-as-chief-commercial-officer/2461990/Mark Aguillard is DermTech, Inc.’s chief commercial officer effective September 19, 2023. Mr. Aguillard will lead DermTech’s overall commercial strategy and execution. Prior to joining is DermTech, Mr. Aguillard served as the chief commercial officer of Epic